APP Pharmaceuticals on Thursday announced that the FDA has cleared its polymyxin B sulfate injection, which is indicated for infections caused by pseudomonous aeruginosa. The drug, a generic version of Bedford Laboratories' Polymyxin B Sulfate, is expected to be on the market in the first quarter of the year.

Full Story:

Related Summaries